Letter to the Editor: In Vitro Activity of Oxazolidinone Against Nontuberculous Mycobacteria in China

Cowman S , van Ingen J , Griffith DE , et al. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J, 2019; 54(1):1900250.

Kwon YS , Daley CL , Koh WJ . Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: Challenges and new approaches. Expert Rev Respir Med, 2019; 13(9):851–861.

Griffith DE , Aksamit T , Brown-Elliott BA , et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007; 175(4):367–416.

Yu X , Huo F , Wang F , et al. In vitro antimicrobial activity comparison of linezolid, tedizolid, sutezolid and delpazolid against slowly growing mycobacteria isolated in Beijing, China. Infect Drug Resist, 2021; 14:4689–4697.

Kim DH , Kim SY , Koh WJ , et al. In vitro activity of oxazolidinone against nontuberculous mycobacteria, including macrolide-resistant clinical isolates. Antimicrob Agents Chemother, 2021; 65(7):e0230620.

Wen S , Gao X , Zhao W , et al. Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China. Int J Infect Dis 2021; 109:253–260.

Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes, 3rd ed. CLSI Standard M24. CLSI: Wayne, PA, USA; 2018.